aurobindo pharma

D-Street Buzz: Oil & gas stocks gain led by IOC, ONGC; Bharti Airtel spikes 4%, HDFC drags

The breadth of the market favoured the advances with 764 stocks advancing and 913 declining while 384 remained unchanged. On the BSE, 1157 stocks advanced, 1297 declined and 142 remained unchanged.

Aurobindo Pharma extends losses on report of a lawsuit against the co in US

The latest lawsuit is a part of growing litigation against the makers and distributors of sartan-based blood pressure lowering drugs in the US, the report said.

Pharma stocks poised for a bounceback; 3 bets for over 20% returns

In coming week any tick above 9,350 on Nifty Pharma index will trigger fresh buying in pharma stocks, Arpan Shah of Monarch Networth Capital said

Aurobindo Pharma expects first biosimilar approval in US in 12-18 months

A biosimilar is a biologic medical product that is almost an identical copy of an original product that is manufactured by a different company

These 3 Indian pharma firms to benefit from warning letter to Mylan's US facility

The slowdown in production at Morgantown site could provide a window of opportunity to Mylan's peers

Aurobindo Pharma to launch oncology, respiratory products in US by 2021

The company is also planning to launch first set of biosimilars and vaccines in growth markets during this time, Aurobindo Pharma said in an investor presentation.

Buy Aurobindo Pharma; target of Rs 875: HDFC Securities

HDFC Securities is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 875 in its research report dated November 14, 2018.

Buy Aurobindo Pharma; target of Rs 909: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 909 in its research report dated November 13, 2018.

Aurobindo inks pact to acquire Australian pharma firm's product

Aurobindo Pharma has said it's wholly-owned subsidiaryhas entered into an agreement to acquire a product under development and related assets from Australia-based Advent Pharmaceuticals Pty Ltd for USD 12.5 million.

Aurobindo Pharm Standalone September 2018 Net Sales at Rs 3,170.39 crore, up 3.14% Q-o-Q

Aurobindo Pharm Consolidated September 2018 Net Sales at Rs 4,751.40 crore, Up 7.11% Q-o-Q.

Aurobindo Pharm Consolidated September 2018 Net Sales at Rs 4,751.40 crore, Up 7.11% Q-o-Q.

Aurobindo Pharma Q2 profit falls 22% YoY to Rs 611.43 crore; revenue rises to Rs 4,751.4 crore

The earnings before interest, taxes, depreciation and amortization was reported at Rs 986.3 crore for the September quarter.

Q2 preview: Muted US business growth likely to hit Aurobindo Pharma's performance

Further, high R&D cost is likely to affect financials as well, one brokerage house wrote in its report.

Market Headstart: Nifty likely to open higher; 3 stocks which could give 7-10% return

Trends on SGX Nifty indicate a positive opening for the broader index in India, a gain of 70.5 points or 0.69 percent. Nifty futures were trading around 11,299-level on the Singaporean Exchange.

Buy or Sell | Expect pull back rally on Nifty above 10,270

Sector-wise, FMCG, IT and Pharma could see a weak trend. Here's Swait Hotkar, Technical Analyst at Nirmal Bang, recommending what to pick in this episode of Buy or Sell.

Podcast | Stock picks of the day: Use rallies to go short on Nifty; 3 stocks which could give 6-7% return

We expect Nifty to continue within a broader range of 10,100-10,700 in the near future and either side decisive breakout would trigger the next directional move.

Aurobindo Pharma Q2 PAT may dip 28.3% YoY to Rs. 560 cr: HDFC Securities

Net Sales are expected to decrease by 3.9 percent Y-o-Y (up 0.3 percent Q-o-Q) to Rs. 4,260 crore, according to HDFC Securities.

Aurobindo Pharma Q2 PAT may dip 23% YoY to Rs. 601.9 cr: ICICI Direct

Net Sales are expected to increase by 4.6 percent Y-o-Y (up 9.1 percent Q-o-Q) to Rs. 4,638.9 crore, according to ICICI Direct.

Aurobindo Pharma gets USFDA nod for infections treatment drug

The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Azithromycin oral suspension 100 mg /5 mL and 200 mg/5 mL, Aurobindo Pharma said in a statement.

Buy or Sell | 10,200 strong support for Nifty; Aurobindo top buy

In our latest episode of Buy or Sell, Sameet Chavan, Chief Analyst at Angel Broking suggest specific stocks likely to yield high returns, such as Aurobindo Pharma among others.

Market Headstart: Nifty likely to open gap-down; 3 stocks which could give 9-12% return

Trends on SGX Nifty indicate a negative opening for the broader index in India, a plunge of 240 points or 2.29 percent. Nifty futures were trading around 10,240-level on the Singaporean Exchange.

Early Diwali sale: 63 of top 100 companies available at 10-40% discount

Indian markets are in the midst of a correction which is likely to extend further, according to experts and hence, there will be plenty of opportunities for investors to enter into quality stocks on declines

Aurobindo Pharma gets nod from South African health authority for HIV drug

The Hyderabad-based drug firm said it has received approval from the South African Health Products Regulatory Authority (SAHPRA) and is now among the first few companies which have received nod for this product.

Aurobindo Pharma shares gain over 1% on SAHPRA approval for HIV drug

Aurobindo is now among the first few companies which has received approval for this product.